Skip to main content

Articles

Recent Articles

A Practical Business Approach to Data Management for Clinical Trial Efficiency
Articles  —  19 May May 2021

A Practical Business Approach to Data Management for Clinical Trial Efficiency

Read More about A Practical Business Approach to Data Management for Clinical Trial Efficiency
A Practical Business Approach to Data Management for Clinical Trial Efficiency
Articles  —  19 May May 2021

A Practical Business Approach to Data Management for Clinical Trial Efficiency

Read More about A Practical Business Approach to Data Management for Clinical Trial Efficiency
GENFIT announces the launch by Labcorp of NASHnext® a novel noninvasive diagnostic test powered by GENFIT’s NIS4™ technology to identify patients with at-risk NASH
Articles  —  12 May May 2021

GENFIT announces the launch by Labcorp of NASHnext® a novel noninvasive diagnostic test powered by GENFIT’s NIS4™ technology to identify patients with at-risk NASH

Read More about GENFIT announces the launch by Labcorp of NASHnext® a novel noninvasive diagnostic test powered by GENFIT’s NIS4™ technology to identify patients with at-risk NASH
GENFIT announces the launch by Labcorp of NASHnext® a novel noninvasive diagnostic test powered by GENFIT’s NIS4™ technology to identify patients with at-risk NASH
Articles  —  12 May May 2021

GENFIT announces the launch by Labcorp of NASHnext® a novel noninvasive diagnostic test powered by GENFIT’s NIS4™ technology to identify patients with at-risk NASH

Read More about GENFIT announces the launch by Labcorp of NASHnext® a novel noninvasive diagnostic test powered by GENFIT’s NIS4™ technology to identify patients with at-risk NASH
Development, Commercialization and Utilization of Companion Diagnostics White Paper
Articles  —  7 May May 2021

Development, Commercialization and Utilization of Companion Diagnostics White Paper

Read More about Development, Commercialization and Utilization of Companion Diagnostics White Paper
Development, Commercialization and Utilization of Companion Diagnostics White Paper
Articles  —  7 May May 2021

Development, Commercialization and Utilization of Companion Diagnostics White Paper

Read More about Development, Commercialization and Utilization of Companion Diagnostics White Paper
Are Payer Assessments Of Innovative Cancer Therapies Optimal Across Europe?
Articles  —  29 April Apr 2021

Are Payer Assessments Of Innovative Cancer Therapies Optimal Across Europe?

Read More about Are Payer Assessments Of Innovative Cancer Therapies Optimal Across Europe?
Are Payer Assessments Of Innovative Cancer Therapies Optimal Across Europe?
Articles  —  29 April Apr 2021

Are Payer Assessments Of Innovative Cancer Therapies Optimal Across Europe?

Read More about Are Payer Assessments Of Innovative Cancer Therapies Optimal Across Europe?
Making Sense of Antisense Oligonucleotide-Based Therapies in Muscular Dystrophies
Articles  —  23 April Apr 2021

Making Sense of Antisense Oligonucleotide-Based Therapies in Muscular Dystrophies

Read More about Making Sense of Antisense Oligonucleotide-Based Therapies in Muscular Dystrophies
Making Sense of Antisense Oligonucleotide-Based Therapies in Muscular Dystrophies
Articles  —  23 April Apr 2021

Making Sense of Antisense Oligonucleotide-Based Therapies in Muscular Dystrophies

Read More about Making Sense of Antisense Oligonucleotide-Based Therapies in Muscular Dystrophies
Quantifying in vivo Biodistribution and Kinetics of Your Biologic or Nanomaterial
Articles  —  23 April Apr 2021

Quantifying in vivo Biodistribution and Kinetics of Your Biologic or Nanomaterial

Read More about Quantifying in vivo Biodistribution and Kinetics of Your Biologic or Nanomaterial
Quantifying in vivo Biodistribution and Kinetics of Your Biologic or Nanomaterial
Articles  —  23 April Apr 2021

Quantifying in vivo Biodistribution and Kinetics of Your Biologic or Nanomaterial

Read More about Quantifying in vivo Biodistribution and Kinetics of Your Biologic or Nanomaterial